Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

46.29USD
4:04pm EDT
Change (% chg)

$-2.39 (-4.91%)
Prev Close
$48.68
Open
$48.79
Day's High
$48.87
Day's Low
$46.08
Volume
3,104,280
Avg. Vol
1,133,933
52-wk High
$66.55
52-wk Low
$46.08

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000... (more)

Overall

Beta: 0.74
Market Cap(Mil.): $49,999.77
Shares Outstanding(Mil.): 1,014.36
Dividend: 0.34
Yield (%): 2.79

Financials

  TEVA.N Industry Sector
P/E (TTM): 32.51 37.66 37.54
EPS (TTM): 1.50 -- --
ROI: 4.12 14.54 13.98
ROE: 5.06 15.32 14.88

BRIEF-Teva Pharma retracts press release on launch of generic Epzicom in U.S.

* Requests that their press release entitled "Teva announces launch of generic Epzicom(reg) tablets in United States" be killed

Sep 28 2016

BRIEF-Teva launches generic epzicom tablets in the U.S.

* Teva announces launch of generic epzicom tablets in the United States Source text for Eikon: Further company coverage:

Sep 28 2016

BRIEF-Teva announces data from second phase 3 study of SD-809

* Teva announces positive top-line data from second phase 3 study of SD-809 in Tardive Dyskinesia (TD)

Sep 22 2016

BRIEF-Teva and regeneron announce global collaboration to develop Fasinumab

* To pay Regeneron $250 million upfront, share equally in global commercial value, ongoing research & development costs of about $1 billion

Sep 20 2016

BRIEF-Regeneron, Teva collaborate to develop, commercialize Fasinumab

* Regeneron and Teva announce global collaboration to develop and commercialize Fasinumab, an investigational NGF antibody for chronic pain

Sep 20 2016

Regeneron, Teva take aim at Lilly/Pfizer pain drug

Sept 20 Regeneron Pharmaceuticals Inc and Israeli drugmaker Teva Pharmaceutical Industries on Tuesday said they would co-develop Regeneron's experimental new type of pain drug and together market the medicine if it succeeds in trials and is approved.

Sep 20 2016

BRIEF-Teva announces results from exploratory 52-week phase 2 PRIDE-HD study of Pridopidine in Huntington disease

* Announces results from exploratory 52-week phase 2 PRIDE-HD study of pridopidine in Huntington disease

Sep 19 2016

BRIEF-Teva launches authorized generic of Cubicin in the U.S.

* Teva strengthens injectables portfolio with the launch of an authorized generic of Cubicin (Daptomycin for injection) in the United States Source text for Eikon: Further company coverage:

Sep 15 2016

Teva Pharm, Intel to study Huntington disease progression

JERUSALEM, Sept 15 Teva Pharmaceutical Industries is collaborating with Intel Corp to develop a wearable device and machine learning platform for Huntington disease patients, Teva said on Thursday.

Sep 15 2016

BRIEF-Teva collaborates with Intel to develop a device for use in huntington disease

Sept 15 Teva Pharmaceutical Ltd Says It Will Deploy The Technology Platform In A Sub

Sep 15 2016

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF77.25 -1.30
Biogen Inc (BIIB.OQ) $305.78 -4.77

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.